Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Affymax Shrinks Quarterly Loss

By R&D Editors | November 10, 2011

PALO ALTO, Calif. (AP) – Biotech drugmaker Affymax Inc. reported a smaller third-quarter loss and said it settled litigation with Johnson & Johnson over its top drug candidate, the anemia treatment peginesatide.

Affymax said it lost $9.8 million, or 28 cents per share, compared with $12 million, or 49 cents per share, a year ago. The company’s research and development costs decreased because it completed clinical trials of peginesatide.

During the quarter it received a $10 million milestone payment from Takeda Pharmaceutical Co. after the Food and Drug Administration accepted their marketing application for peginesatide, a treatment for anemia in patients with chronic kidney failure.

Affymax’s revenue slipped 21 percent to $13.2 million from $16.8 million.

Analysts expected a loss of 32 cents per share on $16.2 million in revenue, according to FactSet.

Affymax also said it settled a lawsuit with Johnson & Johnson’s Janssen Biotech unit over peginesatide. Affymax agreed to pay Janssen $6 million upfront and will make an additional $2 million payment by June 30. It will pay $2.5 million if peginesatide is approved in the U.S. and $2.5 million more if it is approved in Europe. Takeda can reimburse Affymax for up to half of those costs. J&J will also get royalties on sale of peginesatide in Europe, Mexico, Canada, and Japan until mid-2016. Affymax said the royalties will be in the low single digits.

Affymax and Janssen collaborated on research between 1992 and 1995. In October 2010 an arbitration panel determined that Affymax and Janssen co-owned intellectual property related to the drug, including several patents.

The FDA is scheduled to make a decision on peginesatide on March 26. Takeda will pay Affymax $50 million if the drug is approved. In 2011, Affymax said it now expects $25 million to $30 million in payments from Takeda, up from $20 million to $25 million. It also forecast lower operating expenses at $95 million to $100 million, down from $100 million to $105 million.

Date: November 9, 2011
Source: Associated Press

Related Articles Read More >

PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
R&D 100 winner of the day: Portable EnGineered Analytic Sensor with aUtomated Sampling (PEGASUS)
UCLA bioengineers develop new class of human-powered bioelectronics
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars